Biovie Inc. has reported a significant stock purchase by its President and CEO, Do Cuong V. On November 18, 2026, Cuong acquired 2,500 shares of the company at a price of approximately $0.9971 per share. This transaction is noteworthy as it reflects the CEO's confidence in the company's future prospects.

Biovie Inc. operates within the pharmaceutical preparations industry, as classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbols BIVI and BIVIW. Recent filings indicate that Biovie is categorized as a smaller reporting company and a non-accelerated filer.

According to the filing, Cuong's transaction was conducted in the open market, and following this purchase, he now holds a total of 21,117 shares in Biovie. The filing states, "The shares of Common Stock were purchased by the reporting person in an open market transaction." This indicates a direct ownership stake in the company.

This insider transaction may affect investor sentiment and could influence the company's stock performance. Additionally, it highlights ongoing activity within the pharmaceutical industry, where insider trading can often signal confidence or concern about a company's direction.

The filing does not specify what actions may follow this transaction, leaving investors and analysts to speculate on future developments.